Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(15)00486-7
- PMID
- 26725450
- PMCID
- —
- OpenAlex
- W2198922822
- Study type
- Randomised controlled trial
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The paper is relevant to Ebola vaccine development because it provides early human safety and immune-response data for a candidate vaccine during an outbreak context. It is positioned as evidence to support later-phase efficacy studies rather than as a population-level effectiveness assessment.
Structured evidence summary
Research question
The study asked whether a single intramuscular dose of a chimpanzee adenovirus-vectored Ebola Zaire vaccine was safe and immunogenic in healthy adults.
Study design
This was a randomised, double-blind, placebo-controlled, dose-finding phase 1/2a trial conducted at a single center in Lausanne, Switzerland.
Population and setting
The participants were healthy adults aged 18 to 65 years. The trial enrolled 120 people, including a smaller subgroup considered potentially deployable to endemic areas.
Main findings
No vaccine-related serious adverse events were reported. Local and mild to moderate systemic reactions were more common after vaccine than placebo, and the vaccine produced strong antibody and T-cell responses that remained detectable at 6 months; the abstract reports no meaningful difference between the two doses for safety or immunogenicity.
Public-health relevance
The paper is relevant to Ebola vaccine development because it provides early human safety and immune-response data for a candidate vaccine during an outbreak context. It is positioned as evidence to support later-phase efficacy studies rather than as a population-level effectiveness assessment.
Important limitations
The evidence is limited to a phase 1/2a study with a small sample, single-center setting, and 6-month follow-up. Safety comparison for the potentially deployed subgroup was not masked, and this summary is limited to the supplied single-article abstract and metadata; the original paper is needed for decision-grade interpretation.
GIDS interpretation
The article is readily discoverable as an Ebola vaccination trial through its title, journal metadata, and disease/topic classifiers. That indexing provides context only and does not support any live surveillance inference.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.